Ponatinib (Iclusig) returns

Medical Letter on Drugs and Therapeutics

Volumn 56, Issue 1434, 2014, Pages 8-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892762937     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. In brief: ponatinib (Iclusig) marketing and sales suspended. Med Lett Drugs Ther 2013; 55:93.
2. FDA. FDA drug safety communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. Available at www.fda.gov/drugs/ drugsafety/ucm379554.htm. Accessed January 10, 2014.